SCHEMBL2632623

SCHEMBL2632623

COC(=O)CC(N)Cc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.53
MMP2 P08253 3/20 0.51
SLC7A5 Q01650 2/20 0.50
ALPI P09923 1/20 0.50
PKM P14618 1/20 0.50
PTGS1 P23219 1/20 0.50
XIAP P98170 1/20 0.50
ABCB1 P08183 1/20 0.49
LAP3 P28838 1/20 0.49
MMP1 P03956 1/20 0.48
ANPEP P15144 1/20 0.47
DPP4 P27487 1/20 0.47
MAOB P27338 1/20 0.46
SRR Q9GZT4 1/20 0.46
SLC1A3 P43003 1/20 0.46
SLC1A2 P43004 1/20 0.46
SLC1A1 P43005 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6343323 1.00 EPHX1 (0.53) EPHX1MMP2SLC7A5ALPIPKM
SCHEMBL27846893 1.00 EPHX1 (0.53) EPHX1MMP2SLC7A5ALPIPKM
Hydrochloric Acid SCHEMBL3707653 0.98 EPHX1 (0.52) EPHX1MMP2SLC7A5ALPIPKM
Hydrochloric Acid SCHEMBL6343321 0.98 EPHX1 (0.52) EPHX1MMP2SLC7A5ALPIPKM
Trifluoroacetic Acid SCHEMBL28185089 0.92 CTRB1 (0.47) EPHX1MMP2SLC7A5ALPIPKM
Trifluoroacetic Acid SCHEMBL6894530 0.92 CTRB1 (0.47) EPHX1MMP2SLC7A5ALPIPKM
SCHEMBL8298804 0.87 MAOB (0.64) LAP3MAOB
SCHEMBL6506467 0.87 MAOB (0.64) LAP3MAOB
SCHEMBL27488009 0.86 MMP1 (0.49) SLC7A5ALPIPKMPTGS1XIAP
SCHEMBL9834142 0.85 ABCB1 (0.55) MMP2SLC7A5ALPIPKMPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS SERVIER LAB (FR) 2026-01-01 US disclosed
EP-4551566-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS Les Laboratoires Servier (FR) 2025-05-14 EP disclosed
CN-119816491-A New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors 法国施维雅药厂 2025-04-11 CN disclosed
WO-2024008941-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS LES LABORATOIRES SERVIER (FR) 2024-01-11 WO disclosed
WO-2024008941-A1 NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS LES LABORATOIRES SERVIER (FR) 2024-01-11 WO disclosed
EP-3911645-B1 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE UNIV LILLE (FR) 2022-12-07 EP disclosed
WO-2020148403-A1 5-MEMBERED HETEROARYL COMPOUNDS CONTAINING A HYDROXAMATE MOIETY AND THEIR USE UNIVERSITE DE LILLE (FR) 2020-07-23 WO disclosed
US-8877815-B2 Substituted carbamoylcycloalkyl acetic acid derivatives as NEP NOVARTIS AG (CH) 2014-11-04 US disclosed
CN-102471294-B Chiral cyclic beta-amino aryl butyric acid derivative, preparation method thereof and method for preparing chiral beta-amino aryl butyric acid derivative by using same UNITRIS BIOPHARMA CO LTD 2013-11-20 CN disclosed
US-8377949-B2 Quinazolinedione chymase inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-02-19 US disclosed
US-20120122863-A1 Quinazolinedione Chymase Inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-17 US disclosed
US-20120100579-A1 TRIPRENYL PHENOL COMPOUND, PROCESS FOR PRODUCTION OF TRIPRENYL PHENOL COMPOUND, AND THROMBOLYSIS ENHANCER TOKYO UNIVERSITY OF AGRICLATURE AND TECHNOLOGY TLO CO., LTD. (JP) 2012-04-26 US disclosed
US-8110596-B2 Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) 2012-02-07 US disclosed
CN-102212015-A Method for preparing chiral beta-amino arylbutyric acid derivatives SHANGHAI UNITRIS BIOPHARMA CO LTD 2011-10-12 CN disclosed
US-20090216028-A1 Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer TOKYO UNIVERSITY OF AGRICULTURE AND TECHNOLOGY TLO CO., LTD. (JP) 2009-08-27 US disclosed
CN-1043125-A Be used as the aryl urea of the replacement of high-potency sweetener NUTRASWEET CO (US) 1990-06-20 CN disclosed
CN-1008092-B PROCESS FOR PREPARATION OF ENKEPHALINASE INHIBITORS SQUIBB & SONS INC (US) 1990-05-23 CN disclosed
WO-1990002112-A1 SUBSTITUTED ARYL UREAS AS HIGH POTENCY SWEETENERS THE NUTRASWEET COMPANY (US) 1990-03-08 WO disclosed
EP-0355819-A1 Substituted aryl ureas as high potency sweeteners THE NUTRASWEET COMPANY (a Delaware corporation) (US) 1990-02-28 EP disclosed
CN-85101902-A Enkephalinase inhibitor 1987-01-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122863-A1 Quinazolinedione Chymase Inhibitors CMA1, CTSC, TPSG1 EPHX1 1234/4885MMP2 194/4885SLC7A5 535/4885
US-20260001846-A1 SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS BCL2, BCL2A1, BAX EPHX1 3226/4885MMP2 1331/4885SLC7A5 3306/4885
US-20090216028-A1 Triprenyl phenol compound, process for production of triprenyl phenol compound, and thrombolysis enhancer PLAT, F2R, F12 EPHX1 390/4885MMP2 40/4885SLC7A5 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.